Understanding and Reducing Your Risk for AMD
February is Age-Related Macular Degeneration Awareness Month. A serious degenerative eye disease that can cause irreversible vision loss or blindness if left untreated, AMD is the most common reason patients are referred
read more
What to Expect From an Eye Injection
We know the idea of having an injection in your eye can sound scary, but for many retinal diseases, it is the only way we can deliver potentially sight-saving medicine where it
read more
Shining a Spotlight on Age-related Macular Degeneration (AMD)
February is national age-related macular degeneration (AMD) and low vision awareness month. Low vision is a visual impairment that cannot be corrected by standard eyeglasses, contact lenses, medication, or surgery. AMD, a deterioration, or
read more
Three New Clinical Trials Available at Texas Retina
Medical researchers continue to make significant advances in the diagnosis and treatment of retinal conditions, and our physicians remain committed to participating in clinical trials that will improve care for our patients.
read more
New Treatments Available for Geographic Atrophy
We know geographic atrophy (GA) can negatively impact patients’ quality of life and independence. While it still cannot be cured, Texas Retina is excited to finally have two new GA treatment options
read more
Check Out Our New Patient Education Videos!
We know that anything affecting your sight can be scary, and at Texas Retina, we have always believed in treating our patients as we would our own families. That means not only
read more Texas Retina Associates First in U.S. to Dose a Patient in the Phase 2 SIGLEC Trial
On June 1, 2023, Ashkan Abbey, MD, dosed the first patient in the Phase II SIGLEC Trial, a clinical study evaluating AVD-104, a potential new treatment for geographic atrophy (GA) from age-related
read more FDA Approves First Treatment for Geographic Atrophy
On February 17, 2023, the U.S. Food and Drug Administration (FDA) approved intravitreal pegcetacoplan (brand name Syfovre), the first-ever treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Texas Retina
read more
What is Geographic Atrophy?
Approximately 20% of patients with age-related macular degeneration (AMD) will develop a condition called geographic atrophy (GA). It is considered a late stage of AMD and involves chronic, progressive degeneration of regions
read more
Dr. Abbey to Speak at Upcoming Retina World Congress Medical Education Event
On October 24, 2021, Texas Retina Associates’ Ashkan M. Abbey, MD, will serve on a distinguished panel of presenters from across the country for a Retina World Congress continuing medical education (CME)
read more